Vivos Therapeutics, Inc. Business Acquisition, Pro Forma Net Income (Loss)
Vivos Therapeutics, Inc. (VVOS) reported Business Acquisition, Pro Forma Net Income (Loss) of -$7.75 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-20.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2026-05-20
- Vivos Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2026-03-31 was -$7.75M.
- Vivos Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2025-12-31 was -$5.78M.
- Vivos Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2025-09-30 was -$5.47M.
- Vivos Therapeutics, Inc. business acquisition, pro forma net income (loss) for the quarter ending 2025-06-30 was -$5.20M.
- Vivos Therapeutics, Inc. business acquisition, pro forma net income (loss) for fiscal 2025 was -$21.23M.
- Vivos Therapeutics, Inc. business acquisition, pro forma net income (loss) for fiscal 2024 was -$11.95M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 3 month | Business Acquisition, Pro Forma Net Income (Loss) 6 month | Business Acquisition, Pro Forma Net Income (Loss) 9 month | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|---|---|---|
| 2026-03-31 | -$7.75M 10-Q · filed 2026-05-20 | -$13.53M derived: sum of 2 quarters · filed 2026-05-20 | -$19.00M derived: sum of 3 quarters · filed 2026-05-20 | -$24.21M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-12-31 | -$5.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$11.25M derived: sum of 2 quarters · filed 2026-04-15 | -$16.46M derived: sum of 3 quarters · filed 2026-04-15 | -$21.23M 10-K · filed 2026-04-15 |
| 2025-09-30 | -$5.47M 10-Q · filed 2025-11-19 | -$10.68M derived: sum of 2 quarters · filed 2025-11-19 | -$15.45M 10-Q · filed 2025-11-19 | -$18.52M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-06-30 | -$5.20M 10-Q · filed 2025-08-19 | -$9.67M 10-Q · filed 2025-08-19 | -$13.05M derived: sum of 3 quarters · filed 2026-05-20 | -$15.93M derived: sum of 4 quarters · filed 2026-05-20 |
| 2025-03-31 | -$4.47M 10-Q · filed 2026-05-20 | -$7.85M derived: sum of 2 quarters · filed 2026-05-20 | -$10.73M derived: sum of 3 quarters · filed 2026-05-20 | -$12.74M derived: sum of 4 quarters · filed 2026-05-20 |
| 2024-12-31 | -$3.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-15 | -$6.26M derived: sum of 2 quarters · filed 2026-04-15 | -$8.27M derived: sum of 3 quarters · filed 2026-04-15 | -$11.95M 10-K · filed 2026-04-15 |
| 2024-09-30 | -$2.88M 10-Q · filed 2025-11-19 | -$4.89M derived: sum of 2 quarters · filed 2025-11-19 | -$8.57M 10-Q · filed 2025-11-19 | |
| 2024-06-30 | -$2.01M 10-Q · filed 2025-08-19 | -$5.97M 10-Q · filed 2025-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Beyond Air, Inc. (XAIR) | United States | $0.003B | -0.01 |
| NEXGEL, INC. (NXGL) | United States | $0.002B | |
| INVO Fertility, Inc. (IVF) | United States | $0.002B | -0.71 |
| Catheter Precision, Inc. (VTAK) | United States | $0.002B | -0.23 |
| Tenon Medical, Inc. (TNON) | United States | $0.002B | |
| Autonomix Medical, Inc. (AMIX) | United States | $0.004B | |
| Adagio Medical Holdings, Inc. (ADGM) | United States | $0.004B | |
| Profusa, Inc. (PFSA) | United States | $0.002B | |
| OSR Health, Inc. (OSRH) | United States | $0.004B | -0.75 |
| Bluejay Diagnostics, Inc. (BJDX) | United States | $0.004B |